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Abstract
Background: Arginine (ARG) and nitric oxide maintain the mucosal integrity of the intestine in various intestinal
disorders. In the present study, we evaluated the effects of oral ARG supplementation on intestinal structural
changes, enterocyte proliferation and apoptosis following methotrexate (MTX)-induced intestinal damage in a rat.
Methods: Male rats were divided into four experimental groups: Control rats, CONTR-ARG rats, were treated with
oral ARG given in drinking water 72 hours before and 72 hours following vehicle injection, MTX rats were treated
with a single dose of methotrexate, and MTX-ARG rats were treated with oral ARG following injection of MTX.
Intestinal mucosal damage, mucosal structural changes, enterocyte proliferation and enterocyte apoptosis were
determined 72 hours following MTX injection. RT-PCR was used to determine bax and bcl-2 mRNA expression.
Results: MTX-ARG rats demonstrated greater jejunal and ileal bowel weight, greater ileal mucosal weight, greater
ileal mucosal DNA and protein levels, greater villus height in jejunum and ileum and crypt depth in ileum,
compared to MTX animals. A significant decrease in enterocyte apoptosis in the ileum of MTX-ARG rats (vs MTX)
was accompanied by decreased bax mRNA and protein expression and increased bcl-2 protein levels.
Conclusions: Treatment with oral ARG prevents mucosal injury and improves intestinal recovery following MTX-
injury in the rat.
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Background
Mucositis is a debilitating, dose-limiting, and costly side
effect of cancer therapy. Mucositis occurs in 40% of
cancer patients after standard doses of treatment and in
almost 100% of patients treated with high doses of che-
motherapy [1] and can affect the entire gastrointestinal
tract causing discomfort, nausea, vomiting, bloating, diar-
rhoea, ulceration, bleeding and in some cases result in
septicaemia [2]. The mechanisms of mucositis are poorly
understood. It has been suggested that proinflammatory
cytokines, e.g., TNF-a and IL-1b, may be involved in the
amplification phase of intestinal mucositis [3].
Arginine is a non-essential amino acid processed
metabolically by the urea cycle and involved in multiple
metabolic and biologic processes including release of
several hormones, immune response, the regulation of
inflammation, collagen synthesis during wound healing,
and tumor biology [4]. L-Arginine is the precursor for
the formation of nitric oxide (NO), an important signal-
ing molecule involved in neurotransmission, vascular
homeostasis, immune regulation, and host defense [5].
In addition, arginine is an essential metabolic substrate
for immune cells and required for normal lymphocyte
function [6]. Arginine and NO are critical to the normal
physiology of the gastrointestinal tract. Several studies
have suggested that endogenous formation of nitric
oxide maintains the mucosal integrity of the intestine
and protects the gut from injuries from blood-borne
toxins and tissue destructive mediators [7,8]. In a recent
study, we have shown that oral arginine decreases
intestinal injury caused by lipopolysacharide endotoxe-
mia in a rat [9]. In another study, we have demonstrated
* Correspondence: igor-dr@internet-zahav.net
1The Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of
Technology, Laboratory of intestinal adaptation and recovery, Haifa, Israel
Full list of author information is available at the end of the article
Koppelmann et al. BMC Gastroenterology 2012, 12:41
http://www.biomedcentral.com/1471-230X/12/41
© 2012 Koppelmann et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
that oral arginine administration improves mucosal
recovery following intestinal ischemia/reperfusion injury
in the rat [10]. In a recent review, Drover et al. have
described that perioperative administration of arginine
supplemented diets in elective surgical patients results
in a substantial reduction in infectious complications
and shorter hospital length of stay, with no overall effect
on mortality compared with standard care [11].
The purpose of this study was to evaluate the effective-
ness of dietary L-arginine in prevention of methotrexate
(MTX) induced intestinal damage in a rat model and to
investigate the mechanisms involved in the stimulating
effect of arginine on enterocyte turnover including its
effects on cell proliferation and cell death via apoptosis.
Methods
Animals
The experimental protocol was approved by the “Guide
for the Care and Use of Laboratory Animals,” Rappaport
Faculty of Medicine, Technion (Haifa, Israel). Male Spra-
gue-Dawley rats weighing 250-300 g were acclimatized at
21°C on 12-h day and night cycles for a minimum of
1 week before experimentation. The rats had free access to
water and were pair-fed with standard chow.
Experimental design
Animals were randomly assigned to one of four experi-
mental groups of 8 rats each: (1) sham rats (Group A), (2)
sham-ARG rats were pretreated with ARG given in drink-
ing water (2%) for 7 days (Group B), (3) MTX rats, which
underwent methotrexate injury by a single intraperitoneal
injection of 20 μg/kg and were sacrificed 3 days later
(Group C), and (4) MTX-ARG animals, which were pre-
treated with ARG given in drinking water 3 days before
and 3 days after MTX injection (Group D).
Intestinal morphology analysis
The small intestine was removed and divided into two
segments: proximal jejunum (10 from the Treitz liga-
ment) and terminal ileum (10 cm from ileo-cecal junc-
tion). Each segment was weighed, mucosa was scraped
off, weighed and snap frozen in liquid nitrogen. Mucosal
samples (100 mg) were homogenized using Kontes
Tenbroeck Tissue Grinder. DNA and protein were
extracted using TRIZOL reagent as described by Chomc-
zynski [12]. The DNA concentrations were recorded
spectrophotometrically and calculated per cm of bowel
length. Final protein concentration was measured spec-
trophotometrically using a commercially available kit
(Bio-Rad, Protein Assay) and was calculated per cm of
bowel length. Histological sections were prepared from
the jejunal and ileal remnants. Pieces of proximal jeju-
num and terminal ileum near the ileo-cecal junction
were placed in 5% phosphate-buffered formalin, washed
with absolute alcohol, and embedded in paraffin, cut to 5
(m thickness, and stained with hematoxylin-eosin. Fifteen
of longest villi and crypts were selected for the micro-
scopic analysis, using a 10 × 4 magnifying lens.
Enterocyte proliferation and apoptosis
Crypt cell proliferation was assessed using a biotinylated
monoclonal anti-BrdU antibody system provided in a kit
form (Zymed Laboratories, Inc, San Francisco, CA). An
index of proliferation was determined as the ratio of crypt
cells staining positively for BrdU per 10 crypts. Additional
5 μm thick sections were prepared to establish the degree
of enterocyte apoptosis. Immunohistochemistry for
Caspase-3 (Caspase-3 cleaved concentrated polyclonal
antibody; dilution 1:100; Biocare Medical, Walnut Creek,
CA) was performed for identification of apoptotic cells
using a combination of streptovidin-biotin-peroxidase
method and microwave antigen retrieval on formalin-
fixed, paraffin-embedded tissues according to the manu-
facturers’ protocols. For each group, the number of stained
cells was counted in at least ten villi. The apoptotic index
(AI) was defined as the number of apoptotic cells per ten
villi. All measurements were performed by a qualified
pathologist blinded as to the source of intestinal tissue.
Expression of bax and bcl-2 genes (real-time PCR)
Expression of Bax and Bcl-2 levels was determined by
quantitative real-time PCR (7500 Real-Time PCR System,
Applied Biosystems, USA) on cDNA samples using
Cyber Green Master Mix (ROVALAB, Germany) with
the exception of template and primers. Primers for Rattus
norvegicus Bax and Bcl-2 were synthesized by Syntezza
Bioscience ltd. Israel, and 18 s rRNA Control kit from
Eurogentec, EGT Group.
Western blotting
Tissue from jejunum and ileum was homogenized in RIPA
lysis buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM
NaCl, 1% NP-40, 2 mM EDTA, supplemented with a
cocktail of protease and phosphatase inhibitors. Protein
concentrations were determined by Bradford reagent
according to the manufacturer’s instructions. Samples
containing equal amounts of total protein (30 μg) were
resolved by SDS-PAGE under reducing conditions. After
electrophoresis, proteins were transferred to a PVDF
membrane and probed with various primary antibodies to
anti-Bcl-2 antibody (1:1000 dilution, sc-7382), anti-Bax
antibody (1:200 dilution, sc-493), anti-phospho-ERK anti-
body (1:2500 dilution, sc-7383), anti-b-catenin antibody
(1:1000 dilution, sc-7199) and anti-ERK2 antibody (1:1000
dilution, sc-56899). Horseradish peroxidase-conjugated
secondary antibody was purchased from Jackson Immu-
noResearch Laboratories Inc. (West Grove, PA) and an
enhanced chemiluminescent substrate from Biological
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Industries (Kibbutz Beth HaEmek, Israel). The optical den-
sity of the specific protein bands was quantified by using a
densitometer (Vilber Lourmat, Lion, France).
Statistical analysis
The data are expressed as the mean ± SEM. A one-way
ANOVA for comparison, followed by Tukey’s test for
pair-wise comparison was used for statistical analysis.
Prism software was used (GraphPad Software, Inc., San
Diego, CA) and statistical significance was defined as
P < 0.05.
Results
Water, arginine and energy intake
Total water intake was 15-18 ml/rat/day. There was no
significant difference in fluid intake between all experi-
mental groups (15 ml/rat/day in control animals and
18 ml/rat/day in MTX-groups). The amount of additional
protein was 300 mg/rat/a day and additional calorie intake
was 1.2 kcal/rat/day.
Body weight changes
MTX (Group C) rats demonstrated a significant decrease
in final body weight (100 ± 2.6 vs 106 ± 0.4%initial weight,
p < 0.05) compared to control animals (Group A).
Although treatment with oral arginine resulted in a trend
toward increase in final body weight in both sham (Group
B) and MTX (Group D) animals, this trend did not achieve
statistical significance.
Intestinal mucosal parameters
Oral arginine administration in control animals (Group B)
resulted in a mild decrease in bowel weight and mucosal
weight in jejunum and ileum, as well as mucosal DNA
content (33%, p < 0.05) in jejunum compared to control
animals (Table 1). MTX-induced intestinal damage
(Group C) was associated with a significant decrease in
bowel weight in jejunum (26%, p < 0.05) and ileum (20%,
p < 0.05), mucosal weight in jejunum (two-fold decrease,
p < 0.05) and ileum (two-fold decrease 25%, p < 0.05),
mucosal DNA in jejunum and ileum (two-fold decrease,
p < 0.05), and mucosal protein in jejunum (38%, p < 0.05)
and ileum (41%, p < 0.05) compared to control animals
(Group A). Following dietary L-arginine administration
(Group D), MTX-rats demonstrated a significant increase
in bowel weight in jejunum (12%, p < 0.05), bowel (24%,
p < 0.05) and mucosal (30%, p < 0.05) weight in ileum,
ileal mucosal DNA (two-fold increase, p < 0.05) and
Table 1 Intestinal mucosal parameters
CONTR CONTR-ARG MTX MTX-ARG
Bowel weight
(mg/cm/100 mg body weight)
Jejunum 23 ± 1 21 ± 1 17 ± 0.3 * 19 ± 1 *†
Ileum 21 ± 1 19 ± 1 17 ± 1 * 21 ± 1 *†
Mucosal weight
(mg/cm/100 mg body weight)
Jejunum 9.4 ± 0.5 7.6 ± 0.5 * 5.1 ± 0.6 * 6.2 ± 0.6
Ileum 9.1 ± 0.5 6.7 ± 0.5 * 4.7 ± 0.5 * 6.1 ± 0.6 *†
Mucosal DNA
(μg/cm/100 mg body weight)
Jejunum 45 ± 7 30 ± 4 * 22 ± 5 * 25 ± 3 *
Ileum 47 ± 6 52 ± 4 19 ± 4 * 38 ± 9 †
Mucosal protein
(μg/cm/100 mg body weight)
Jejunum 94 ± 21 60 ± 11 58 ± 10 * 58 ± 5 *
Ileum 54 ± 10 44 ± 8 32 ± 5 * 51 ± 8 †
Villus height (μm)
Jejunum 434 ± 29 345 ± 56 314 ± 33 * 413 ± 18 †
Ileum 371 ± 26 287 ± 19 * 217 ± 52 * 300 ± 23 *†
Crypt depth (μm)
Jejunum 183 ± 17 131 ± 8 * 112 ± 4 * 126 ± 11
Ileum 161 ± 16 120 ± 8 * 101 ± 15 * 131 ± 10 *†
CONTR- control, MTX-methotrexate, ARG-arginine
* P < 0.05 All groups vs CONTR rats, † P < 0.05 MTX-ARG vs MTX rats.
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protein (59%, p < 0.05) compared to MTX-untreated ani-
mals (Group C).
Microscopic bowel appearance
MTX rats showed severe villous atrophy, epithelial flat-
tening, extensive crypt loss and signs of crypt remodel-
ing, which was accompanied by marked cellularity and
an increased number of blood vessels in the stroma
(Figure 1A). The proliferative zone in MTX-rats moved
progressively upwards in the crypts toward the crypt-vil-
lus junction (Figure 1B). At the same time, the prolifera-
tive zone of MTX-ARG rat was only mildly affected,
showing a slight shift upwards within the crypts.
Although the mucosa was still severely damaged, MTX-
ARG rats showed the presence of newly formed crypts
and regeneration.
Villus height and crypt depth significantly decreased in
jejunum (28% and 39%, correspondingly, p < 0.05) and
ileum (42% and 37%, correspondingly, p < 0.05) in MTX-
rats compared to control animals (Table 1). Dietary
L-arginine exerted different effects on the microscopic
intestinal appearance in control and MTX animals. In
control rats, oral arginine (Group B) resulted in a mild
but significant decrease in villus height and crypt depth
in jejunum and ileum compared to control animals
(Group A). In MTX rats, dietary L-arginine (Group D)
attenuated the negative effect of methotrexate on
mucosal architecture. MTX-ARG rats showed greater vil-
lus height in jejunum (32%, p < 0.05) and ileum (38%
increase, p < 0.05), and crypt depth in ileum (30%
increase, p < 0.05) compared to MTX-animals (Group C).
Cellular proliferation and apoptosis
CONTR-ARG rats showed a trend toward a decrease in
cell proliferation; however, this trend was not statisti-
cally significant (Figure 1). MTX intestinal damage
(Group C) resulted in a significant decrease in entero-
cyte proliferation rates in jejunum (128 ± 12 vs 197 ±
14 BrdU positive cells/10crypts, p < 0.05) and ileum
(133 ± 21 vs 210 ± 22 BrdU positive cells/10crypts, p <
0.05) when compared to control animals (Group A).
Although treatment with dietary arginine of MTX-ani-
mals (Group D) resulted in a 10% increase in cell prolif-
eration rates in jejunum and ileum, this change was not
statistically significant.
The frequency of apoptotic cells was increased in the
animals following MTX-induced damage in jejunum
(1.8 ± 0.2 vs 0.8 ± 0.37 apoptotic cells/1- villi, p < 0.05)
and ileum (1.5 ± 0.3 vs 0.6 ± 0.13 apoptotic cells/1- villi,
p < 0.05) compared to control rats (Figure 1). Treatment
with dietary arginine of MTX-animals (Group D)
resulted in a significant two-fold decrease in cell apopto-
sis in both jejunum and ileum (p < 0.05) compared to
MTX-nontreated animals (Group C).
Expression of apoptosis related genes
CONTR-ARG (Group B) rats showed a small but signifi-
cant increase in bax mRNA (pro-apoptotic factor) expres-
sion in jejunum (33%) and ileum (53%) compared to
control animals (Figure 2). MTX rats (Group C) demon-
strated a two-fold increase in bax mRNA expression in
jejunum and ileum (p < 0.05) as well as a two-fold decrease
in bcl-2 gene (anti-apoptotic protein) expression (p < 0.05)
in jejunum compared to control animals (Group A). Treat-
ment with arginine resulted in a significant decrease in bax
mRNA expression in jejunum (38%, p < 0.05) and ileum
(41%, p < 0.05) and a concomitant decrease in bcl-2 gene
expression in ileum (44%, p < 0.05) compared to MTX
animals (Figure 3).
Western blotting
Although western blot analysis of proliferation and
apoptosis markers has demonstrated a similar tendency
both in jejunum and ileum, more representative changes
were observed in the terminal ileum. Western blot ana-
lysis (Figure 4) illustrated a significant decrease in bcl-2
protein levels as well as a significant increase in bax
protein in MTX rats compared to control animals.
These findings correlate with augmented cell apoptosis
in MTX-animals compared to control rats. Decreased
cell proliferation in this group coincided with decreased
b-catenin levels. Treatment with arginine resulted in a
significant increase in bcl-2 protein levels as well as a
significant decrease in bax protein levels without
changes in p-ERK and b-catenin levels compared to
MTX rats. These qualitative and quantitative changes
are in agreement with the mRNA expression data and
with decreased apoptosis and unchanged proliferation in
ileum following ARG administration.
Discussion
In the last two decades, arginine has attracted major
interest since it has been identified as the natural sub-
strate of nitric oxide, and is now recognized to play a
major role in many regulation processes. Nitric oxide is a
multifunctional intercellular messenger molecule that
plays an important role in a variety of physiological pro-
cesses. Nitric oxide is synthesized from L-arginine by the
inducible nitric oxide synthase (iNOS). Arginine and
nitric oxide are critical to the normal physiology of the
gastrointestinal tract and maintain the mucosal integrity
of the intestine in various intestinal disorders. Arginine
stimulates intestinal cell migration and intestinal protein
synthesis through a focal adhesion kinase dependent
mechanism in vitro [13]. Arginine supplementation
enhances intestinal growth and development in weanling
piglets [14]. Dietary supplementation with arginine sti-
mulates small intestinal mucosal recovery following
experimental radiation enteritis [15] and accelerates ulcer
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healing in experimental ulcerative ileitis [16]. In a recent
study, we have shown that oral arginine decreases intest-
inal injury caused by lipopolysacharide endotoxemia in a
rat [9]. In another study, we have demonstrated that oral
arginine administration improves mucosal recovery fol-
lowing intestinal ischemia-reperfusion injury in a rat
[10]. The mechanisms of these positive effects are still
unclear; however, a stimulating effect of appropriate
amounts of NO on enterocyte proliferation and a sup-
pressive effect on enterocyte death via apoptosis may be
considered as one of them.
The role of arginine in prevention of chemotherapy-
induced intestinal damage is unclear. Hämäläinen Met al
have shown recently that chemotherapy inhibites iNOS
expression, and subsequent NO production, in a dose-
dependent manner at therapeutically achievable drug
concentrations in a human colon epithelial cell line [17].
In a recent experiment, Gulgun et al. have demonstrated
that proanthocyanidin, arginine and glutamine supple-
mentation had a positive effect in the protection of the
small intestine from methotrexate-induced injury [18].
The mechanisms of this effect were not investigated. In a
CONTR
MTX
MTX-ARG
CONTR
MTX
MTX-ARG
A B
50 ?m
Figure 1 A. Staining with H@E. Intestinal injury caused by MTX. MTX rats demonstrated a significant epithelial atrophy (thick arrows) and
signs of crypt remodeling (thin arrows) which were accompanied by marked cellularity and an increased number of blood vessels (arrowheads)
in the stroma. Following ARG administration rats showed less significant epithelial atrophy and crypt remodeling compared to MTX rats. B. BrdU
staining (cell proliferation). Control rats show normal crypt compartment. The proliferative zone in MTX-rats moved progressively upwards in the
crypts toward the crypt-villus junction. The proliferative zone of MTX-ARG rat was only mildly affected showed the presence of newly formed
crypts and signs of regeneration. CONTR-control, MTX-methotrexate, ARG-arginine.
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recent clinical trial, Izaola et al. have shown that arginine
and glutamine enhanced formula decreases the rate of
radiotherapy-induced oral mucositis in patients with
head and neck cancer [19].
Methotrexate is the most commonly used anti-meta-
bolite agent in clinical oncology practice. Since ARG
maintains the mucosal integrity of the intestine in
various intestinal disorders, we hypothesized in the pre-
sent study that this amino acid could prevent intestinal
mucosal injury or/and improve intestinal recovery fol-
lowing MTX-induced mucositis. Alterations in bowel
and mucosal weights, mucosal DNA and protein content
and histological appearance were measured. BrdU was
used in our experiment to determine an index of crypt
Figure 2 Effects of MTX and arginine on crypt cell proliferation and apoptosis. The number of labeled cells in 10 well-oriented,
longitudinal crypts per section from each rat was determined using light microscopy. Identification of apoptotic cells was performed using
immunohistochemistry for Caspase-3. The apoptotic index is expressed as the percentage of apoptotic cells per 10 villi. Values are mean ± SEM.
CONTR- control, MTX-methotrexate, ARG-arginine. * P < 0.05 MTX and MTX-ARG vs CONTR rats, † P < 0.05 MTX-ARG vs MTX rats.
Figure 3 Effect of arginine on bax and bcl-2 mRNA expression in gut mucosa following methotrexate induced intestinal damage.
Results are expressed as the ratio of the investigated bax and bcl-2 mRNA to ERK. Values are mean ± SEM. CONTR- control, MTX-methotrexate,
ARG-arginine. * P < 0.05 MTX and MTX-ARG vs CONTR rats, † P < 0.05 MTX-ARG vs MTX rats.
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cell proliferation. Immunohistochemistry for caspase-3
was used to characterize enterocyte apoptosis. We have
demonstrated that a single dose of MTX caused a severe
mucosal injury in the small bowel, indicated by severe
villous atrophy, epithelial flattening, intensive crypt loss
and signs of crypt remodeling, which was accompanied
by marked cellularity and an increased number of blood
vessels in stroma. In addition, treatment with MTX
resulted in significant mucosal hypoplasia. A decrease in
bowel and mucosal weight, mucosal DNA and protein,
and decrease in villus height support this conclusion.
Parallel decreases in mucosal DNA and protein indicate
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Figure 4 Effect of MTX and dietary arginine on b-catenin, p-ERK, bax and bcl-2 protein levels in ileum (Western blotting). Values are
presented as a ratio to ERK protein level and are expressed as a percentage of the control group. CONTR- control, MTX-methotrexate, ARG-
arginine.
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that the smaller mucosal mass of MTX animals can be
attributed to cellular hypoplasia. Histologically, villus
height decreased in response to MTX administration,
suggesting decreased absorptive surface area. Mucosal
DNA content as well as the enterocyte proliferation
index decreased significantly in both jejunum and ileum
following MTX administration. MTX is an analog of
folic acid and works by attaching to dehydrofolate
reductase to inhibit DNA production. As a result crypt
proliferation in the small bowel is inhibited. In addition,
the proliferative zone in MTX-rats moved progressively
upwards in the crypts toward the crypt-villus junction.
The mechanism responsible for this effect is poorly
understood. Verburg and coworkers have shown in
MTX-treated rats that BrdU-positive cells are not
restricted to the crypts but are also found in up to one-
third of the length of the villi due to migration of the
cells [20]. Our data suggest that MTX animals had
lower b-catenin levels which fits with decreased cell pro-
liferation. Extensive experimental evidence suggests that
Wnt/b-catenin signaling plays a central role in main-
taining the intestinal stem-cell niche and in regulating
differentiation of stem cells within the intestinal epithe-
lium toward either enterocytes or one of three secretory
cell lineages (Paneth, goblet, or enteroendocrine cells
[21]. Cell loss in the small intestine MTX-induced
mucositis is mainly regulated by programmed cell death.
Our results show that the intrinsic pathway, with its reg-
ulation by the bcl-2 family of proteins, was altered by
MTX consistent with changes in cell apoptosis: the
mRNA levels of the pro-apoptotic gene bax increased,
while those of the antiapoptotic bcl-2 gene decreased.
With regard to the protein level, qualitative and quanti-
tative changes were in agreement with mRNA expres-
sion. Bax protein levels were significantly up-regulated
while bcl-2 protein levels were down regulated in MTX-
treated rats compared to control animals. These changes
correlate with the enhanced enterocyte apoptosis during
MTX-induced mucositis.
Results of the present study show that dietary arginine
protects the intestinal mucosa from damage caused by
MTX. While MTX rats showed severe villous atrophy,
epithelial flattening, extensive crypt loss and signs of
crypt remodeling, marked cellularity and an increased
number of blood vessels in stroma, arginine-treated rats
showed more preserved architecture as well as the pre-
sence of newly formed crypts and regeneration. While
the proliferative zone in MTX-rats moved progressively
upwards in the crypts toward the crypt-villus junction,
the proliferative zone of MTX-ARG rats was only mildly
affected, showing a slight shift upwards within the
crypts. In addition, exposure to oral arginine signifi-
cantly enhanced intestinal recovery following MTX-
induced damage. This is evident from the significant
increase in bowel and mucosal, increased DNA and pro-
tein content in ileum. Increased mucosal weight without
changes in mucosal surface area may suggest that muco-
sal hyperplasia rather than bowel enlargement or intest-
inal muscle hypertrophy is responsible for the increased
intestinal mass. Increase in mucosal DNA and protein
along with hypertrophy of the individual cells which we
have demonstrated morphometrically is characteristic of
tissues undergoing increased cell proliferation or repair.
Histologically, marked increases in villus height in both
jejunum and ileum suggest increased absorptive surface
area and closely correlate with increased cell mass. The
present data suggest that arginine did not change signifi-
cantly mucosal proliferation in functioning intestine, but
decreased significantly cell apoptosis rate, which may
represent the main mechanism that maintains mucosal
structure following MTX-induced damage. Our results
show that the intrinsic pathway, with its regulation by
the bcl-2 family of proteins, was altered by arginine in
accordance with changes in cell apoptosis: the mRNA
and protein levels of the pro-apoptotic bax decreased,
while those of the antiapoptotic bcl-2 protein levels
increased. Correspondingly, bax/bcl-2 ratio decreased in
MTX-ARG rats compared to MTX animals, suggesting
increased enterocyte survival. Further investigation is
needed to define the regulation of this special apoptotic
state with respect to the Fas/Fasl-mediated extrinsic
pathway.
The mechanism of the positive effects of arginine is
unclear. In non-operated, non-stressed animal, total
food intake is 20-25 g/rat/day, total protein intake is
about 6 g/rat/day, and total energy intake is 100 kcal/
rat/day [22]. We do not believe that an additional 300
mg/rat/day of protein (vs 6 g of total protein) as well as
additional energy of 1.2 kcal/rat (vs total 100 kcal/rat/
day) may have influenced the results. The limitation of
the current experiment is a lack of isonitrogenous MTX
group. Therefore, this study is not able to prove that
arginine supply limits intestinal damage. It was pre-
viously reported that other amino acids (like glutamine,
glycine or histidine) have protective effects on intestinal
mucosa during chemotherapy or inflammatory condi-
tions. An additional MTX-isonitrogenous amino acid
group will be added in future study to determine
whether other amino acids have similar effects.
Conclusions
In a rat model of methotrexate-induced mucositis,
administration of dietary arginine prevents intestinal
damage, decreases cell death via apoptosis and acceler-
ates intestinal recovery. These preliminary observations
suggest that oral arginine may have clinical value in pre-
venting or reducing the severity of chemotherapy-
induced mucositis.
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